Since it bypasses the digestive system, the body absorbs it quickly and efficiently
Maybe such a thing exists right in your body right now
In September 2023, FDA placed "Thymosin Beta-4, Fragment (LKKTETQ)," the substance sold as TB-500, on Category 2 of its interim 503A bulk drug substances list, meaning FDA identified significant safety concerns and would not permit licensed compounding pharmacies to use it
This limited selection may force patients into suboptimal choices based on availability rather than clinical appropriateness
The second category included substances considered too risky for compounding
Without clinical approval, clear safety data, or regulation, the risks far outweigh the short-term gains